Viking Therapeutics (VKTX)
NASDAQ:VKTX
Want to see VKTX full AI Analyst Report?
VKTX Stock Chart & Stats
$35.20
$0.22(0.67%)
At close: 4:00 PM EST
$35.20
$0.22(0.67%)
Day’s Range― - ―
52-Week Range$22.96 - $43.15
Previous CloseN/A
Volume7.75M
Average Volume (3M)1.95M
Market Cap
$3.53B
Enterprise Value$3.40B
Total Cash (Recent Filing)$602.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Jul 29, 2026EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.14
Shares Outstanding116,105,644
10 Day Avg. Volume2,146,521
30 Day Avg. Volume1,947,386
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.34K
Enterprise Value/Ebitda-7.20
Forecast
1Y Price Target
$93.70Price Target Upside166.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetNear-zero debt materially lowers financial distress risk for a clinical‑stage biotech that lacks product revenue. A conservatively levered balance sheet increases strategic optionality—enabling funding rounds, partnerships, or milestone-based deals without heavy interest obligations, durable over 2–6 months.
Focused Metabolic Drug PipelineA concentrated pipeline aimed at obesity/metabolic indications aligns with large, structural market demand and allows the company to allocate R&D resources efficiently. Specialized expertise and program focus increase the chance that clinical progress can translate into durable licensing or commercialization opportunities.
Governance Stability And OversightRobust shareholder support for the board and auditor reinforces continuity in strategy, financial reporting, and executive incentives. Stable governance reduces execution risk on multi‑year clinical plans and supports consistent oversight—an enduring positive for clinical development timelines and partner negotiations.
Bears Say
Pre-revenue With Widening Net LossesZero product revenue combined with sharply expanding net losses is a lasting structural weakness: without commercialization or consistent partnership income, the company must rely on capital markets to fund operations. Continued losses erode shareholder value and increase long‑term financing dependency.
Accelerating Cash BurnA rapidly rising negative operating/free cash flow trajectory is a durable constraint: it shortens runway, forces frequent financing or deal-making, and limits strategic flexibility. High burn increases dilution risk and may compel hurried partnerships or asset sales rather than optimal development choices.
Eroding Equity Base / DilutionSubstantial decline in shareholders' equity signals repeated financings or accumulated losses, reducing the capital buffer and shareholder value. Persistent dilution is a structural risk for long‑term holders, weakening downside protection and potentially limiting the company's ability to fund late‑stage trials without further equity issuance.
Viking Therapeutics News
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $22.96 and its highest was $43.15 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.53B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Jul 29, 2026 which is in 37 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Apr 29, 2026. The company reported -$1.37 earnings per share for the quarter, missing the consensus estimate of -$0.976 by -$0.394.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -1.23.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 116,105,644 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$1.37 in its last earnings report, missing expectations of -$0.976. Following the earnings report the stock price went down -0.479%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.70 (166.19% Upside)
$93.70 (166.19% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 86.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.60%
12-Months-Change
Fundamentals
Return on Equity
-71.31%
Trailing 12-Months
Asset Growth
-29.84%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
VKTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.View all VKTX earnings summariesVKTX Stock 12 Month Forecast
Average Price Target
$93.70
▲(166.19% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
2.88% Insiders
18.34% Mutual Funds
9.83% Other Institutional Investors
55.86% Public Companies and Individual Investors